» Articles » PMID: 26553431

Morphine-induced MOR-1X and ASF/SF2 Expressions Are Independent of Transcriptional Regulation: Implications for MOR-1X Signaling

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2015 Nov 11
PMID 26553431
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, multiple μ-opioid receptor (MOR) isoforms have been identified that originate from a single gene, OPRM1; however, both their regulation and their functional significance are poorly characterized. The objectives of this study were to decipher, first, the regulation of alternatively spliced μ-opioid receptor isoforms and the spliceosome components that determine splicing specificity and, second, the signaling pathways utilized by particular isoforms both constitutively and following agonist binding. Our studies demonstrated that the expression of a particular splice variant, MOR-1X, was up-regulated by morphine, and this coincided with an increase in the essential splicing factor ASF/SF2. Structural comparison of this isoform to the prototypical variant MOR-1 revealed that the unique distal portion of the C-terminal domain contains additional phosphorylation sites, whereas functional comparison found distinct signaling differences, particularly in the ERK and p90 RSK pathways. Additionally, MOR-1X expression significantly reduced Bax expression and mitochondrial dehydrogenase activity, suggesting a unique functional consequence for MOR-1X specific signaling. Collectively, these findings suggest that alternative splicing of the MOR is altered by exogenous opioids, such as morphine, and that individual isoforms, such as MOR-1X, mediate unique signal transduction with distinct functional consequence. Furthermore, we have identified for the first time a potential mechanism that involves the essential splicing factor ASF/SF2 through which morphine regulates splicing specificity of the MOR encoding gene, OPRM1.

Citing Articles

Modulation of OPRM1 Alternative Splicing by Morphine and HIV-1 Nef.

Donadoni M, Huang W, Yarandi S, Burdo T, Chang S, Sariyer I J Neuroimmune Pharmacol. 2021; 17(1-2):277-288.

PMID: 34420144 PMC: 8859008. DOI: 10.1007/s11481-021-10009-4.


Novel Roles of Non-Coding RNAs in Opioid Signaling and Cardioprotection.

Melo Z, Ishida C, Goldaraz M, Rojo R, Echavarria R Noncoding RNA. 2018; 4(3).

PMID: 30227648 PMC: 6162605. DOI: 10.3390/ncrna4030022.

References
1.
Ahn S, Shenoy S, Wei H, Lefkowitz R . Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem. 2004; 279(34):35518-25. DOI: 10.1074/jbc.M405878200. View

2.
Schulz R, Eisinger D, Wehmeyer A . Opioid control of MAP kinase cascade. Eur J Pharmacol. 2004; 500(1-3):487-97. DOI: 10.1016/j.ejphar.2004.07.010. View

3.
Krainer A, Conway G, Kozak D . The essential pre-mRNA splicing factor SF2 influences 5' splice site selection by activating proximal sites. Cell. 1990; 62(1):35-42. DOI: 10.1016/0092-8674(90)90237-9. View

4.
Wang J, Johnson P, Persico A, Hawkins A, Griffin C, Uhl G . Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett. 1994; 338(2):217-22. DOI: 10.1016/0014-5793(94)80368-4. View

5.
Caceres J, Stamm S, Helfman D, Krainer A . Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science. 1994; 265(5179):1706-9. DOI: 10.1126/science.8085156. View